FDA Rounds Up Biliary Stent Makers On Off-label Promotion
This article was originally published in The Gray Sheet
Executive Summary
FDA gathered biliary stent manufacturers to discuss how to prevent off-label marketing for peripheral vascular disease while it clarifies the regulatory pathway for vascular stents